A step in right direction, but CT pharmacist, industry expert say Trump’s pharma deal doesn’t address larger problem

CTNewsJunkie – Friday, October 3, 2025
By Brian Scott-Smith

President Donald Trump and pharmaceutical manufacturing giant Pfizer announced a deal this week to cut the cost of the company’s prescription drugs covered by Medicaid, the joint federal and state medical program for people with limited income and resources.

Trump also introduced TrumpRX, an online service that will sell drugs directly to consumers at discounted prices, although precise details and when this service will start were not part of the announcement.

The announcement is part of a Trump administration effort to lower the price of prescription drugs for Americans and to get the type of pricing that other countries have been receiving from pharmaceutical companies for years. The administration also says it is trying to unravel the complex nature of how drugs are priced in the US, which they said is unique in that the process involves Pharmacy Benefit Managers (PBMs).

But Doug Hoey, president of the National Community Pharmacists Association (NCPA), says the president needs to go further.

Click here to read the entire article.